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Even though ubiquitination controls a plethora of cellular processes, modifications by 
linear polyubiquitin have so far only been linked with acquired and innate immunity, 
lymphocyte development and genotoxic stress response. Until now, a single E3 ligase 
complex (LUBAC), one specific deubiquitinase (OTULIN) and a very few substrates 
have been identified. The existing methods for the study of lysine-based 
polyubiquitination are not suitable for the detection of linear polyubiquitin-modified 
proteins. Here, we present a novel approach to discovering linear polyubiquitin-
modified substrates by combining lysine-less internally tagged ubiquitin (INT-Ub.7KR) 
with SILAC-based mass spectrometry. We applied our approach in TNFα-stimulated T-
REx HEK293T cells and afterwards validated newly identified linear polyubiquitin 
targets. Moreover, we demonstrated that linear polyubiquitination of the novel LUBAC 
substrate TRAF6 is essential for the NFκB signalling. Overall, we have established a 
powerful method for the detection of linear polyubiquitin substrates. 
 
Post-translational modification by ubiquitin (Ub) regulates fundamental cellular 
processes, including protein stability, DNA repair, inflammation and immune response1,2. 
Apart from mono- and multiple monoubiquitination, all 7 internal Ub lysine (K) residues can 
form K-specific Ub linkages, thus forming polyUb chains with distinct structures, assembly 
machineries and functions in the cell3. Additionally, the N-terminal methionine (M) of Ub can 
form a peptide bond with the terminal glycine (G) of another Ub moiety, generating linear 
polyUb chains4.  
Even though its basal cellular levels are very low5,6, linear polyubiquitination can be 
rapidly induced in the cell, eliciting a specific cellular response to a given stimulus. These 
stimuli include TNFα7, heat stress response8 and bacterial infection9, with linear 
polyubiquitination being crucial in inducing inflammatory, acquired and innate immune 
responses10, genotoxic stress response and Parkinson´s disease11. Additionally, numerous 
cellular processes require timely regulated and coordinated activation of linear 
polyubiquitination, such as survival of mature T cells12, late thymic T-cell differentiation13 
and B-cell development and activation14 . 
The only E3 ligase complex described so far to be able to generate linear polyUb 
chains is LUBAC (Linear Ubiquitin Assembly Complex) and consists of three proteins: 
catalytic subunit RNF31/HOIP15,16, RBCK1/HOIL-1L and SIPL1/SHARPIN17-19, whereas 
OTULIN (FAM105B or GUMBY) is the main deubiquitinating enzyme (DUB) highly 
specific for linear Ub chains20,21. 
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Only a handful of linear polyUb-modified substrates has been identified so far7,18,22-24, 
including K63-linked polyUb chains leading to the generation of mixed, K63/M1 hybrid 
polyUb linkages25. Nevertheless, these few proteins (including NEMO) have already been 
linked with several severe diseases, such as X-linked anhidrotic ectodermal dysplasia with 
immunodeficiency (XR-EDA-ID)26-28, justifying the need for an approach allowing the 
identification of novel linear polyUb targets and related processes. 
The most widely used approach for the identification of ubiquitinated proteins is Ub 
remnant profiling29-31. Unfortunately, GGK-specific monoclonal antibodies29-31 do not 
recognise the characteristic GGMQIFVK signature peptides of linear polyubiquitination after 
tryptic cleavage. Additionally, the other existing methods have limitations for the 
identification of linear polyubiquitination substrates: a) N-terminally tagged Ub constructs32-34 
prevent linear polyUb chain assembly due to the requirement for a free M1 residue to build 
linear polyUb chain, b) the use of tandem linear polyUb-binding domains (UBDs) for the 
enrichment of linear polyUb chains is limited to mild cellular lysing conditions, leading to the 
high background in mass spectrometry (MS) analyses and resulting in a large number of false 
positive hits; an additional disadvantage of linear UBDs is that they can also bind K63-linked 
Ub chains to a certain extent, and c) the two currently available linear polyUb-specific 
antibodies are not optimal. The Genentech-generated antibody 1F11/3F5/Y102L can, to a 
certain extent, recognise and capture K63-linked polyUb chains5, while the Lub9 antibody is 
not suitable for immunoprecipitation (IP) experiments, thus limiting its applicability only to 
confirmation of already identified linear polyUb targets14. 
We describe herein a novel approach for the specific enrichment of linear polyUb-
modified substrates, which enabled the identification of novel linear polyUb targets, including 
ATR, BRAP, LGALS7, PLAA, SEPT2, HDAC6, VDAC1 and TRAF6. Moreover, we could 
demonstrate that linear polyubiquitination of TRAF6 is essential for proper IL1β-dependent 
NFκB signalling. 
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RESULTS 
Generation of INT-Ub for the Study of Linear Polyubiquitination. As an internal tag 
within Ub we chose STREP-tag® II, flanked on each side by the short serine-alanine (SA) 
linker, which was incorporated instead of arginine 54 (R54) residue of Ub (Figure 1A). We 
chose STREP-tag® II because this short, almost biochemically inert tag strongly interacts with 
the engineered streptavidin Strep-Tactin®, even under denaturing conditions. Since internally 
tagged Ub (INT-Ub) can build any type of polyUb chain, we also generated INT-Ub, having 
all 7 K residues replaced by R (INT-Ub.7KR). Even though this INT-Ub.7KR variant can also 
monoubiquitinate target proteins and add terminal Ub moiety to any type of polyUb chains, it 
can be efficiently incorporated at multiple positions only within a single Met1-linked polyUb 
chain, thus enabling the enrichment of linear polyUb-modified proteins (Supplementary 
Figure 1A). 
Evaluation of INT-Ub Functionality in vitro. To determine the functionality of INT-Ub, we 
investigated if the presence of the internal tag affected the main structural and functional 
features of Ub. We used NMR spectroscopy (Figure 1B) and circular dicroism 
(Supplementary Figures 1B-1C) to validate the structural integrity of INT-Ub. In all of our 
measurements INT-Ub variants display highly similar spectra compared to wild-type Ub, 
indicating that the secondary and tertiary structures of the recombinant INT-Ub are almost 
identical to wild-type Ub. Therefore, the overall fold of Ub is not compromised by the internal 
tag. We could also demonstrate that recombinant INT-Ub, unlike unconjugatable INT-
Ub.∆GG mutant, can form various polyUb chains (Figure 1C, Supplementary Figures 1D-
1E). Additionally, INT-Ub can bind UBDs that recognise single Ub moieties (Supplementary 
Figure 1F), with the internal tag also not affecting the ability of linear diUb to bind to linear 
polyUb-specific UBD UBAN (Ubiquitin binding in ABIN and NEMO)35 (Figure 1D and 
Supplementary Figure 1G). Moreover, recombinant INT-diUb could be cleaved by Ub chain-
unspecific DUB fragment USP2-cc (Figure 1E)36 and linear polyUb-specific DUB OTULIN 
(Figure 1F, Supplementary Figures 1H-1I). 
Evaluation of INT-Ub Functionality in vivo. As INT-Ub was shown to be functional in 
vitro, we next evaluated its functionality in vivo. Towards that aim, we generated T-REx 
HEK293T and T-REx HeLa cell lines inducibly expressing low amounts of wild-type INT-
Ub, INT-Ub.7KR or INT-Ub.∆GG mutant, in order to ensure the presence of INT-Ub variants 
only as minor fractions of the total cellular Ub pool (Supplementary Figure 2A). As shown in 
Figure 2A, high molecular weight (HMW) Ub species, indicative of polyubiquitinated 
substrates, were visible in the case of INT-Ub and INT-Ub.7KR, contrary to INT-Ub.∆GG. 
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Taking advantage of the STREP-tag® II position between residues K48 and K63, we 
identified GG-K48-INT-Ub and GG-K63-INT-Ub peptides in the INT-Ub sample by MS 
approach, confirming the INT-Ub presence within polyUb chains in vivo (Figure 2B). 
Moreover, we could demonstrate that pulled-down INT-Ub, unlike INT-Ub.∆GG, is enriched 
in ubiquitinated substrates by detecting endogenous PAF15 (PCNA Associated Factor 15), 
which is known to be mono- and double monoubiquitinated37 (Figure 2C). Another important 
aspect to rule out was if INT-Ub variants, particularly INT-Ub.7KR, perturb cellular 
functions. As a model process, we chose the NFκB signalling pathway, since it is highly 
regulated by ubiquitination, with linear polyubiquitination of NEMO being crucial for NFκB 
activation7,18. Upon TNFα stimulation, expression of INT-Ub variants did not affect nuclear 
translocation of NFκB dimers compared to the empty vector control (Figures 2D-E). 
Additionally, we did not observe any significant difference in the transcriptional activity of 
NFκB in any cell line, except for INT-Ub.∆GG (Figure 2F and Supplementary Figure 2B). 
Therefore, we concluded that the stable cell lines inducibly expressing INT-Ub variants were 
appropriate for further in vivo studies. 
Finally, we induced the formation of linear polyUb chains in cells by several approaches: 
transient transfection of OTULIN siRNA (Figure 3A), catalytic-inactive OTULIN mutant 
C129A (Figure 3B) or HOIP/HOIL-1L (Figure 3C), as well as TNFα treatment (Figure 3D) in 
doxycycline-induced INT-Ub.7KR T-REx HEK293T cells. In all the cases, the amount of 
pulled-down HMW Ub species was increased compared to control conditions (Figure 3A-D). 
Furthermore, samples with transiently transfected OTULIN C129A mutant had increased 
amounts of HMW STREP-tag® II-containing species, indicating the enrichment of INT-
Ub.7KR (Figures 3E). To verify that the HMW Ub species indeed contained linear polyUb, 
samples were immunoblotted with the Lub9 antibody (Figure 3F and Supplementary Figure 
2C), further confirming the presence of linear polyUb-modified substrates. Moreover, we 
could demonstrate the presence of HMW species of the known LUBAC substrate NEMO in 
INT-Ub.7KR PD (Supplementary Figure 2D) upon TNFα treatment, confirming that INT-
Ub.7KR enables enrichment of linear polyUb-modified proteins. 
Identification of Novel Linear Polyubiquitin Targets. For our MS screen, we chose TNFα 
stimulation as the well-established physiological stimulus7,38 for the induction of linear 
polyubiquitination (Figure 4A and Supplementary Figure 3A). For the initial MS experiment, 
cells were treated with TNFα for 15 min (Supplementary Table 1). Due to the relatively low 
SILAC ratios in the MS screen (Supplementary Figure 3B), we further optimised the 
procedure by modifying lysis/PD buffer, by replacing Strep-Tactin® with the third generation 
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of Strep-Tactin® XT resins (IBA), as well as by generating a new set of SILAC-labelled T-
REx HEK293T cell lines expressing INT-Ub variants. Moreover, the time of TNFα 
stimulation was decreased to 10 min, for optimal induction of linear polyubiquitination39. 
During MS measurements of three independent experimental replicates, a total of 1,695 
protein groups were quantified at FDR of 1% at protein and peptide level (Supplementary 
Table 2). Correlation of measured SILAC ratios was high between replicates of INT-Ub/INT-
Ub.∆GG and INT-Ub/INT-Ub.7KR (Pearson Correlation Coefficient 0.77-0.85; 
Supplementary Figure 3C). Correlation was lower between replicates of INT-Ub.7KR/INT-
Ub.∆GG (Pearson Correlation Coefficient 0.36-0.45), which may be attributed to a lower 
number of significantly changing ratios and explained by the fact that linear 
polyubiquitination is a very rare cellular event. As expected, KEGG and GOMF annotation 
enrichment analyses showed significant over-representation of Ub-related processes and 
proteins, further confirming that INT-Ub variants are functional (Figure 4B-C). Interestingly, 
protein functions related to systemic lupus erythematosus, an autoimmune disease recently 
linked with linear polyubiquitination and LUBAC40, were significantly enriched. Moreover, 
the MS dataset showed statistically significant overrepresentation of proteins linked with 
Parkinson’s disease. PARKIN has already been linked with inflammation and shown to 
interact with LUBAC to regulate both LUBAC activity41 and its recruitment to the 
mitochondria, resulting in abrogated IFNβ production42. Therefore, KEGG enrichment 
analysis indirectly suggests that the MS dataset was indeed enriched in linear polyUb-
modified proteins. The putative linear polyUb-modified substrate selection was focused on 
proteins preferentially present in INT-Ub (L) and INT-Ub.7KR (M) SILAC-labelled inducible 
T-REx HEK293T cells, in comparison to INT-Ub.∆GG (H) SILAC-labelled cells (which were 
used as a negative MS control) (Figure 4D and Supplementary Table 2). Since both INT-Ub 
and INT-Ub.7KR could be incorporated into linear polyUb chains, INT-Ub/INT-Ub.7KR 
(L/M) ratio was considered as the supporting selection criterion. For the validation of the 
INT-Ub approach, we chose several candidates with SILAC ratios equal or above 2, such as 
ATR, BRAP, LGALS7 and PLAA. To test the sensitivity of our method, we also included 
several proteins found near MS background in both preliminary and triplicate MS 
experiments, such as SEPT2, HDAC6, VDAC1 and TRAF6 (the latter protein was identified 
only in the preliminary MS screen, due to much lower expression level in the second set of T-
REx HEK293T cell lines (Supplementary Figure 3D). 
Validation of Putative Linear Polyubiquitin-modified Substrates. Since there is no well-
established method for the confirmation of protein modification by linear polyUb, we 
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performed several complementary approaches to validate novel substrates. For our MS 
screens we used TNFα to induce linear polyubiquitination. We therefore reasoned that, even 
if additional, unidentified linear polyUb-specific E3 ligases exist in the cell, we would 
preferentially identify LUBAC-dependent substrates. 
First, for the majority of them, we could show HMW species migrating above protein bands, 
both on total cell lysate (TCL) level and upon IP, only in the presence of the active LUBAC 
complex, indicative of (presumably linear) polyubiquitination. No HMW species were 
observed when catalytic-dead LUBAC (HOIP C885A/HOIL-1L) was used (Supplementary 
Figure 4A, and data not shown). Furthermore, we could show that candidates, for which we 
could purify MBP- or GST-fusions of sufficient quality, could bind overexpressed LUBAC 
subunits HOIP and HOIL-1L (Supplementary Figure 4B). Next, we utilised the recombinant 
tandem of 3 NEMO UBAN domains (superUBAN), to pull-down linear polyUb-modified 
substrates. Upon LUBAC overexpression, the amount of HMW HA-tagged TRAF6 pulled 
down with the superUBAN was significantly increased, while the HMW species of the other 
HA-tagged substrates only bound to superUBAN when LUBAC was co-expressed (Figure 
5A). Binding to HMW Ub species of putative substrates was specific, since it was abolished 
when NEMO Ub-binding deficient mutant F305A (superUBAN F305A) was used (Figure 
5A). Moreover, we could observe linear polyUb HMW species above all the HA- and MYC-
tagged putative LUBAC substrates when we immunoprecipitated them under denaturing 
conditions from the samples with ectopically expressed LUBAC complex (Figure 5B). 
Furthermore, we used 1F11/3F5/Y102L antibody5, to immunoprecipitate linear polyUb-
modified proteins under denaturing conditions from the samples containing overexpressed 
active LUBAC. We could detect HMW species above substrates with anti-HA antibody, 
strongly indicating linear polyubiquitination of putative LUBAC substrates (Figure 5C). 
Moreover, we performed an in vitro ubiquitination assay with recombinant active LUBAC 
and recombinant candidates. TRAF6 is an adaptor protein and E3 ligase which generates 
K63-linked polyUb chains and ubiquitinates itself as well as several proteins including 
NEMO and AKT143,44. Moreover, deacetylase HDAC6 has also been suggested to possess 
intrinsic E3 ligase activity45. Thus, an additional control was applied for TRAF6 and HDAC6. 
We could show that SEPT2, HDAC6, VDAC1 and TRAF6 are polyubiquitinated by LUBAC 
in vitro (Supplementary Figure 4C). Also, the observed increase of wild-type TRAF6 
ubiquitination in the presence of LUBAC was decreased when samples were additionally 
treated with active OTULIN (Supplementary Figure 4D), further confirming its linear 
ubiquitination. 
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We analysed the TRAF6 sample (from Figure 5B) by MS and could identify the characteristic 
linear polyUb peptide GGMQIFVK (Supplementary Figure 4E and Supplementary Table 1). 
As the final proof, we immunoprecipitated linear polyUb-modified proteins under denaturing 
conditions from the samples containing ectopic LUBAC complex and detected HMW species 
of several endogenous putative substrates (Supplementary Figure 4F). 
The Functional Significance of TRAF6 Linear Polyubiquitination. Despite relatively low 
enrichment of TRAF6 in MS screen, TRAF6 proved to be very potent MS candidate during 
the evaluation of putative linear polyUb-modified substrates. Therefore, we hypothesised that 
TNFα (originally used in our MS experiment) might not be the optimal physiological 
stimulus for the linear polyubiquitination of TRAF6. Since TRAF6 is involved in IL-1β-
dependent NFκB signalling46, we compared the ability of IL-1β and TNFα to induce linear 
polyubiquitination of TRAF6. Our data show that IL-1β-dependent linear polyubiquitination 
of TRAF6 is stronger than the one induced by TNFα  (Figure 6A). When we additionally 
silenced HOIP expression by siRNA approach, IL-1β failed to induce linear 
polyubiquitination of TRAF6 (Supplementary Figure 5A), confirming that LUBAC modifies 
TRAF6 with linear polyUb chains. Next, we tested if E3 ligase activity of TRAF6 is a 
prerequisite for its linear polyubiquitination. We could demonstrate that recombinant 
catalytically inactive TRAF6 C70A mutant is also modified by LUBAC (Figure 6B). Thus, 
TRAF6 E3 ligase activity is not required for its subsequent linear polyubiquitination, with 
LUBAC directly modifying TRAF6 by linear polyUb chains, and not requiring priming with 
K63-linked chains. By MS, we identified three K-residues of TRAF6 ubiquitinated upon 
LUBAC overexpression: one within coiled-coil motif that was previously reported (K33931) 
and two novel sites within MATH domain (K497 and K518) (Figure 6C, Supplementary 
Figure 5B and Supplementary Table 1). Interestingly, K339 and K497 are conserved among 
species, suggesting their physiological significance. When we tested the ability of 
recombinant TRAF6 C70A and TRAF6 C70A K339/K497/K518R mutants to be modified by 
LUBAC in vitro (Supplementary Figures 5C-5D), triple K339/K497/K518R TRAF6 mutant 
failed to be ubiquitinated. Similarly, immunoprecipitated TRAF6 K339/K497/K518R mutant 
could not be efficiently modified by linear polyUb chains upon IL-1β stimulation (Figure 
6D), confirming that the identified residues of TRAF6 are the major targets for LUBAC-
mediated polyubiquitination. To further study the importance of linear polyubiquitination of 
TRAF6 in NFκB pathway, we tested phosphorylation and degradation of IκBα 
(Supplementary Figure 5E), as well as NFκB transcriptional activity (Figure 6E) in TRAF6-/- 
MEFs reconstituted with various TRAF6 mutants (Supplementary Figure 5F). As expected, 
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degradation of IκBα in IL-1β-stimulated TRAF6-/- MEFs reconstituted with either empty 
vector or TRAF6 C70A was abolished, confirming the crucial role of TRAF6 E3 ligase 
activity in IL-1β-induced NFκB signalling. Reconstitution of TRAF6-/- MEFs with wild-type 
TRAF6 restored phosphorylation and degradation of IκBα. Interestingly, TRAF6-/- MEFs 
reconstituted with TRAF6 K339/K497/K518R mutant could activate the NFκB pathway but 
could not sustain the activating effect on the pathway. Expression of TRAF6 K32-518R 
mutant also resulted with the impaired IκBα degradation. The effect of both TRAF6 K-
deficient mutants on NFκB transcriptional activity is even more striking, as both TRAF6 
K339/K497/K518R and TRAF6 K32-518R inhibit IL-1β-induced NFκB activity. Therefore, 
both TRAF6 E3 ligase activity and its linear polyubiquitination are essential for proper IL-1β-
induced NFκB signalling. 
 
DISCUSSION 
Knowledge about the recently discovered linear polyUb modification is limited by a lack of 
adequate methods that permit identification of linear polyUb-modified proteins. Here, we 
introduce a K-less internally tagged Ub approach combined with MS, to identify novel linear 
polyUb targets in a simple and robust manner. 
Ub is rather small, highly conserved eukaryotic protein with the majority of its surfaces being 
required for the interaction with Ub machinery (E1, E2, E3, DUB) or UBD-containing 
proteins. Nevertheless, our choice of the insertion point and insertion tag within Ub fully 
maintains the structural and functional integrity of Ub both in vitro and in vivo, thereby 
representing the first report of the functional internally tagged Ub. 
In order to test our method, we shortly stimulated cells with TNFα5 and performed Strep-
Tactin® PD under denaturing conditions. We identified several novel linear polyUb-modified 
proteins, significantly expanding the number of known linear polyUb targets. Since proteins 
found near MS background (i.e. TRAF6 and VDAC1) were also shown to be modified by 
linear polyUb chains, INT-Ub.7KR approach has proven to be a potent and sensitive method 
for the discovery of linear polyUb-modified proteins. 
The major limitations of our approach are related to MS detection sensitivity, as well as 
protein abundance of linear polyUb targets in tested cell lines. Usually, only a small pool of 
the protein is modified by linear polyUb chains. If the protein is expressed at low levels, MS 
signals from very low abundant modified proteins will be close to noise levels and will not 
have high SILAC ratios. 
The E3 ligase complex LUBAC is so far the only known enzyme known to generate linear 
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polyUb chains. Nevertheless, INT-Ub.7KR approach enables identification of both LUBAC-
dependent and even LUBAC-independent linear ubiquitination, since it does not rely on using 
LUBAC during the screen. By combining INT-Ub.7KR with other stimuli (such as DNA 
damage-inducing compounds, heat shock, various pathogen infections) it is possible to 
identify stimulation-specific linear polyubiquitination substrates (and in that way, novel 
processes regulated by linear polyubiquitination), which can be both LUBAC-dependent, and 
potentially LUBAC-independent. 
Since INT-Ub.7KR maintains Ub fold and does not lead to cellular toxicity when expressed at 
low levels, the generation of knock-in animal models would enable the study of linear 
polyubiquitination during development and its cellular roles in both normal and pathological 
conditions. 
Moreover, identification of novel linear polyUb targets, beyond a handful of proteins 
identified since 20067,18,22-24, will hopefully enable the development of targeted therapy for 
diseases caused by impaired linear polyubiquitination. 
Overall, INT-Ub.7KR approach will significantly contribute to the understanding of until now 
largely underestimated spectrum of linear polyubiquitination, expanding the current view of 
its cellular roles. 
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FIGURE LEGENDS 
Figure 1. The design and in vitro validation of INT-Ub. (A) Ub molecule with an insertion 
point of STREP-tag® II (black) and the following color-coded residues: K (red), M (orange), 
G76 (blue) and I44 (yellow). This Figure was generated with PyMOL software by modifying 
the 1UBQ.pdb file. (B) A comparison of 1D 1H NMR spectra of INT-Ub with unmodified 
Ub. (C) Testing the ability of INT-Ub to form various polyUb chains in in vitro ubiquitination 
assays. INT-Ub.∆GG served as a negative control. (D) Examination of interaction between 
INT-diUb and UBAN by pull-down assay. (E) In vitro deubiquitination assay with 
recombinant INT-diUb and DUBs USP2-cc or (F) OTULIN. Blot images for Figures 1C-1F 
were cropped to improve the conciseness of the presentation (full blots are available in 
Supplementary Figure 6). 
Figure 2. In vivo validation of INT-Ub. (A) Comparison of INT-Ub (lane 1), INT-Ub.7KR 
(lane 2) and INT-Ub.∆GG (lane 3) abilities to conjugate into polyUb chains in vivo. (B) MS 
identification of GG-K48-INT-Ub and GG-K63-INT-Ub peptides in INT-Ub IP sample. 
MS/MS spectra of the GG-K48-INT-Ub (top panel) and GG-K63-INT-Ub (lower panel) 
peptides are shown. (C) Comparative pull-down assay to test the ability of INT-Ub and INT-
Ub.∆GG to enrich polyubiquitinated substrates. Mono- and double monoubiquitinated forms 
of PAF15 were present in INT-Ub PD, but not in INT-Ub.∆GG PD. (D) Effect of INT-Ub 
variants on p65 nuclear translocation upon TNFα (20 ng/ml, 30 min) stimulation. Analysis of 
p65 translocation into nucleus by measuring its abundance in cytoplasmic and nuclear cellular 
fractions in T-REx HEK293T cell lines expressing various Ub variants. PCNA and GAPDH 
were used as nuclear and cytoplasmic markers, respectively. (E) Quantification of (D) by 
ImageJ software. Results are shown as means and s.e.m. (n=3). n.s=no statistically significant 
difference (p>0.05), determined by the two tailed Student’s t-test. (F) Effect of INT-Ub 
variants on NFκB transcriptional activity upon TNFα (20 ng/ml, 10 h) stimulation. 
Measurement of NFκB transcriptional activity by luciferase assay in T-REx HEK293T cell 
lines expressing various Ub variants. Results are shown as means and s.e.m. (n=3). *p<0.05, 
n.s=no statistically significant difference (p>0.05), determined by the two tailed Student’s t-
test. Blot images for Figures 2A, 2C and 2D were cropped to improve the conciseness of the 
presentation (full blots are available in Supplementary Figure 6). 
Figure 3. The use of lysine-less INT-Ub for the identification of novel LUBAC 
substrates. Effect of OTULIN silencing by siRNA (A), OTULIN C129A mutant 
overexpression (B), LUBAC components overexpression (C), and TNFα treatment (D) on the 
abundance of HMW Ub species in INT-Ub.7KR Strep-Tactin® PD, compared to control 
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conditions. (E) As in (B), but sample was immunoblotted with anti-STREP antibody. (F) As 
in (A), but sample was immunoblotted with anti-Lub9 antibody to detect linear 
polyubiquitination. Blot images for Figure 3 were cropped to improve the conciseness of the 
presentation  (full blots are available in Supplementary Figure 7). 
Figure 4. Mass spectrometry-based identification of novel linear polyUb-modified 
substrates. (A) Schematic representation of the SILAC-based MS proteomic approach for the 
identification of linear polyUb-modified substrates upon 10 min of TNFα stimulation. (B) 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis and (C) Gene 
Ontology (GO) annotation enrichment analysis of proteins upregulated in MS analysis 
performed in (A). The bar plot shows significantly over-represented KEGG and GO 
molecular function (GOMF) terms, respectively. The enriched KEGG pathways and GOMF 
terms were identified according to their enrichment (Fisher´s exact test, p<0.01). (D) Scatter 
plots shown as a function of protein intensity and SILAC ratios (left: L/H, middle: L/M and 
right: M/H) for MS data in (A) and Supplementary Table 2. SILAC ratios of log21 are 
marked in red. Putative LUBAC substrates selected for the final validation are indicated in the 
plots. The number of quantified protein pairs are marked in left upper part of each plot. 
Figure 5. Validation of novel linear polyUb-modified substrates. (A) Pull-down assay 
between either GST, GST NEMO UBANx3 or GST NEMO UBANx3 F305A mutant and 
HMW species of HA-tagged putative linear polyUb-modified substrates, which were 
transiently co-overexpressed with LUBAC components in HEK293T cells. (B) Analysis of  
the presence of HMW linear polyUb-modified species of either HA- or MYC-tagged putative 
substrates by denaturing IP. Putative substrates were transiently co-overexpressed with HOIP 
and HOIL-1L in HEK293T cells. (C) Verification of the presence of HMW species of HA-
tagged putative substrates by linear Ub IP. HA-tagged putative substrates were transiently co-
overexpressed with active LUBAC components in HEK293T cells. For experiments (A-C) 
HEK293T cells transfected only with tagged putative substrates and empty vector were used. 
Blot images for Figure 5 were cropped to improve the conciseness of the presentation (full 
blots are available in Supplementary Figures 8-10). 
Figure 6. TRAF6 is a novel LUBAC substrate in NFκB signalling. (A) Denaturing IP 
comparing IL-1β and TNFα for their efficiency to induce linear polyubiquitination of TRAF6 
in TRAF6-/- MEFs reconstituted with HA-TRAF6. (B) In vitro ubiquitination assay with 
recombinant HOIP and HOIL-1L and a catalytically inactive TRAF6 C70A mutant. (C) 
Schematic representation of mouse TRAF6. Ubiquitinated residues identified by MS are 
shown as yellow stars. Below: alignment of the TRAF6 region surrounding the modified K 
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residues in selected vertebrates. (D) Denaturing IP from TRAF6-/- MEFs reconstituted with 
either HA-TRAF6 or HA-TRAF6 K339,497,518R to compare their linear polyubiquitination 
upon IL-1β (10 ng/ml, 5 min) in vivo. (E) Effect of TRAF6 variants on NFκB transcriptional 
activity. TRAF6-/- MEFs expressing various TRAF6 variants were starved for 16 h and 
stimulated with IL-1β (10 ng/ml) for 10 h and subjected to a luciferase assay. Results are 
shown as means and s.e.m. (n=4). **p<0.01, *p<0.05, determined by the two tailed Student’s 
t-test. Blot images for Figure 6A, 6B and 6D were cropped to improve the conciseness of the 
presentation (full blots are available in Supplementary Figure 11). 
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ONLINE METHODS 
Cloning and Antibodies. The lists of generated and received plasmids and antibodies are 
available respectively in Supplementary Tables 3 and 4. 
Cell Lines. Cell lines HEK293T, T-REx HEK293T (T-REx™-293) and T-REx HeLa (T-
REx™-HeLa) were purchased respectively from ATCC and Invitrogen. Early passages were 
propagated, frozen at -150°C and aliquots were used for a limited number of passages. 
TRAF6-/- MEFs were obtained from Dr Jun-Ichiro Inoue. All cells were regularly checked for 
Mycoplasma infection using Venor®GeM Classic from Minerva Biolabs GmbH (Ltd.). 
Purification of MBP-, GST-, HIS- and STREP-tag® Protein Fusions. Various MBP and 
GST fusions were purified as shown previously48. STREP-tag® INT-Ub proteins were 
purified according to Qiagen’s protocol. Briefly, a bacterial pellet was thawed and 
resuspended in buffer NP (50 mM NaH2PO4 and 300 mM NaCl; pH 8.0) together with 1 
mg/ml lysozyme and 3 U/ml benzonase. After incubation on ice (30 min) lysate was 
sonicated, centrifuged (10000 g, 20 min, 4°C) and supernatant incubated with Strep-Tactin® 
Sepharose® (IBA, 1 h, 4°C with rotation). INT-Ub proteins bound to Strep-Tactin® 
Sepharose® were washed with buffer NP and eluted with buffer NPD (50 mM NaH2PO4, 300 
mM NaCl and 2.5 mM desthiobiotin; pH 8.0). Proteins for structural characterisation by CD-
spectroscopy were further purified by size exclusion chromatography using a Superdex S75 
column (GE Healthcare) in 50 mM HEPES (pH 7.4) and 150 mM NaCl. Fractions of highly 
pure Ub variants were identified by SDS-PAGE and subsequently concentrated using 
Vivaspin® Protein Concentrators (GE Healthcare). The proteins GST-UBE2S-UBD, GST-
AMSH, GST-NIeL, GST-CBL RF, MBP-HOIP RBR-C and 6xHIS-USP2-cc were purified as 
previously described36,49-53. After purification, UBE2S-UBD, OTULIN and NIeL were then 
respectively cleaved with PreScission™ (GE Healthcare) and TEV (Invitrogen) proteases to 
remove GST moiety. HOIL-1L-6xHIS, HOIP-6xHIS, 6xHIS-SEPT2, 6xHIS-VDAC1 and 
6xHIS-TRAF6, in addition to its mutants, were purified as previously described23. 
GST and MBP Pull-down Assays. HEK293T cells were transiently transfected with 
indicated plasmids using GeneJuice® (Merck Millipore). Twenty-four to forty-eight hours 
post transfection cells were lysed in a lysis buffer (50 mM HEPES, pH 7.5; 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 10 mM ZnCl2, 10% glycerol, 1 % Triton X-100, 25 mM NaF, 2 
mM NEM, 1 mM PMSF and complete protease and phosphatase inhibitors (Roche)). Cell 
lysates were incubated with either GST- or MBP-fused proteins bound respectively to 
glutathione sepharose beads or amylose resin. After overnight incubation, samples were 
washed three times in a lysis buffer and eluted from resins by incubation in a 1x LDS buffer 
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supplemented with β-mercaptoethanol (10 min, 70°C). To test direct interactions, either 
eluted or cleaved recombinant GST- or MBP-tagged proteins were incubated respectively 
with MBP- or GST-fused proteins bound to amylose resin or glutathione sepharose resin in an 
incubation buffer (20 mM Tris-HCl, pH 8.4; 150 mM NaCl, 2.5 mM CaCl2, 10 % glycerol, 1 
% Triton X-100 and 1 mM DTT) at 4°C. After 4 h incubation, samples were washed three 
times in an incubation buffer and eluted from resins by incubation in a 1x LDS buffer 
supplemented with β-mercaptoethanol (10 min, 70°C). 
SuperUBAN Pull-down Assays. The assay was modified from23. Briefly, GST-tagged 
superUBAN (UBANx3) and superUBAN F305A (UBANx3 F305A) were purified as 
described above. HEK293T cells were transfected with indicated constructs using 
GeneJuice®. Twenty-four hours post transfection cells were lysed in a pull-down buffer (50 
mM Tris-HCl, pH 7.4; 150 mM NaCl, 1 % NP-40, 0.5 % DOC, 10 mM NEM and complete 
protease and phosphatase inhibitors (Roche)), sonicated for 20 s at 10 % and treated with 
benzonase. Protein concentrations were measured and adjusted, and lysates were then 
precleared with GST protein bound to glutathione sepharose resins (1 h, 4°C with rotation). 
Cleared lysates were then incubated with GST, GST UBANx3 or GST UBANx3 F305A 
bound to glutathione sepharose (overnight, 4°C with rotation). Samples were washed three 
times in a pull-down buffer and eluted from resins by incubation in a 1x LDS buffer 
supplemented with β-mercaptoethanol (10 min, 70°C). In cases where samples were prepared 
for MS analysis, they were additionally washed twice in ddH2O supplemented with 2 mM 
NEM before elution. 
In vitro Ubiquitination Reaction. The enzymes 6xHIS-E1, UBCH5a, UBCH5c, 6xHIS-
UBC13/UEV1 (all Boston Biochem) and UBCH7 (Merck Millipore) were purchased. MBP-
HDAC6 was purified as described above followed by overnight cleavage with factor Xa at 
room temperature. Reactions contained 200 ng E1, 400 ng UBCH5c, 1 µg purified 6xHIS-
HOIL-1L/HOIP, 1 µg 6xHIS-SEPT2, 1 µg 6xHIS-VDAC1, 2 µg MBP-HDAC6, 1 µg 6xHIS-
TRAF6 variant, 10 µg Ub, 2 mM ATP, 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2 and 2 mM 
DTT. The assay was performed at 37°C for 3 h and stopped by adding a 1x LDS buffer 
supplemented with β-mercaptoethanol. Reactions with UBE2S-UBD and AMSH, NIeL, CBL 
RF, HOIP RBR-C and USP2-cc were performed as previously described36,49-52. All the other 
reactions were performed by incubating E1 (150 ng), E2 (300 ng), E3 (2 µg), Ub or INT-Ub 
variants (1 µg) with or without 2 mM ATP in in vitro ubiquitination buffer (50 mM Tris-HCl, 
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pH 7.5; 5 mM MgCl2, 2 mM DTT) for 1 h at 37°C. To stop reactions, a 1x LDS buffer 
supplemented with β-mercaptoethanol was added. 
Deubiquitinase Assays. Reactions with USP2-cc and OTULIN were performed as described 
previously36,54. 
CD Measurements. Far-UV CD spectra were recorded on a Jasco J-815 spectropolarimeter 
fitted with a cell holder thermostatted by a CDF-426S Peltier unit. All CD measurements were 
made in 50 mM sodium phosphate buffer (pH 7.4) at 20°C using fused silica cuvettes with 1 
mm path lengths (Hellma, Jena, Germany). The spectra were recorded with 0.2 nm resolution 
and baseline corrected by subtraction of the appropriate buffer spectrum. CD intensities are 
presented as the CD absorption coefficient calculated on a mean residue weight basis 
(∆εMRW)55. In order to visualise the overlapping shape of all four Ub variants, the spectra of 
INT-Ub.7KR were multiplied by 1.3, which accounts for a slight overestimation of the protein 
concentration. 
NMR Spectroscopy. All measurements were performed at 293 K in 20 mM HEPES (pH 7.4), 
50 mM NaCl, 10% D2O on a Bruker AV600 spectrometer. 
Preparation of Inducible Cell Lines for MS Analysis. Stable inducible T-Rex HEK293T 
cell lines were metabolically labelled by SILAC (stable isotope labelling by amino acids in 
cell culture) approach. The stable T-REx HEK293T cell lines INT-Ub, INT-Ub.7KR and 
INT-Ub.∆GG were cultured in media containing heavy L-Arg (R10)/L-Lys (K8) (“heavy”), 
medium L-Arg (R6)/L-Lys (K4) (“medium”) and light L-Arg (R0)/L-Lys (K0) (“light”), as 
indicated in Figure 4A and Supplementary Figure 4A. When kept in medium containing 
zeocin (300 µg/ml) and blasticidin (10 µg/ml), INT-Ub expression was silenced. 
Strep-Tactin® Pull-down. A Strep-Tactin® Pull-down (PD) was performed as follows: stable 
T-REx HEK293T cell lines were either transfected and/or treated as indicated in the text and 
expression of various INT-Ub mutants induced by doxycycline treatment (1 µg/ml; 24 h). 
Cells were lysed in either a denaturing buffer (20 mM Tris-HCl, pH 7.5; 50 mM NaCl, 1 mM 
EDTA, 0.5 % NP-40, 0.5 % SDS, 0.5 % sodium deoxycholate, 1 mM DTT, 10 mM NEM and 
a 1x protease inhibitor cocktail) or a modified denaturing buffer (lacking DOC). Cells 
harvested in a modified denaturing buffer were additionally sonicated for 35 s at amplitude 40 
%. After benzonase treatment, protein concentration was adjusted and samples precleared 
with Superflow resin (30 min, 4°C). Precleared lysates were incubated with prewashed Strep-
Tactin® resins (2 h, 4°C) and then subjected to three washing steps in a denaturing buffer. 
Finally, proteins were eluted by incubation in a 1x LDS buffer supplemented with β-
mercaptoethanol (10 min, 70°C). 
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Immunoprecipitation. HA-IP was performed as Strep-Tactin® PD with the exception that 
anti-HA agarose conjugate was used. Linear Ub IP was performed as described previously5. 
Additionally, linear Ub IP samples were washed twice with ddH2O supplemented with 10 
mM NEM before elution in a 1x LDS buffer supplemented with β-mercaptoethanol (10 min, 
70°C). MYC-IP was performed similar to Strep-Tactin® PD, with the exception that cells 
were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.; 150 mM NaCl, 1 % NP-40, 0.5 % SDS, 
0.5 % sodium deoxycholate, 10 mM NEM and a 1x protease inhibitor cocktail) and lysates 
were subsequently incubated with 0.25 µg of c-Myc antibody and protein G agarose. 
Immunoblotting. For all the experiments apart from linear Ub IP, immunoblotting was 
performed as follows: proteins were separated by SDS-PAGE and transferred to either 0.45 
µm or 0.22 µm nitrocellulose membrane by wet transfer (200 mA, 2 h). Membranes were 
blocked either in 5 % BSA in TBS-T or in 5 % milk in TBS-T and probed with indicated 
primary antibodies overnight at 4°C or for 1 h at RT. Next, membranes were washed in TBS-
T, incubated in an appropriate HRP-conjugated secondary antibody for 1 h at RT and washed 
three times in TBS-T and then twice in TBS. Western Blotting Luminol reagent (Santa Cruz 
Biotechnologies) or Lumigen TMA-6 (GE Healthcare) were used for antibody visualisation. 
To visualise linear polyubiquitin fraction, immunoblotting was performed as described 
previously5. For linear Ub IP, endogenous levels of modified proteins were visualised with 
Clean-Blot IP Detection Reagent (Thermo Fisher Scientific). 
Preparation of Samples for MS Analysis. An expression of various INT-Ub variants was 
induced by doxycycline (1 µg/ml; 24 h) and followed by 16 h starvation in a medium lacking 
FBS. For preliminary MS, experiment cells were stimulated with TNFα (20 ng/ml, 15 min) 
and harvested in a denaturing buffer (20 mM Tris-HCl, pH 7.5; 50 mM NaCl, 1 mM EDTA, 
0.5 % NP-40, 0.5 % SDS, 0.5% sodium deoxycholate, 1 mM DTT, 10 mM NEM and a 1x 
protease inhibitor cocktail (Roche)) After benzonase treatment, lysates were precleared with 
prewashed Superflow resins (30 min, 4°C). Protein concentration was measured and lysates 
were merged in 1:1:1 ratio, followed by incubation with prewashed Strep-Tactin® resins (2 h, 
4°C). Resins were then washed three times in a denaturing buffer and then twice in distilled 
water. Bound proteins were eluted from the Strep-Tactin® resin by incubation in a 1x LDS 
buffer supplemented with β-mercaptoethanol (10 min, 70°C). In the case of the additional 
triplicate MS experiment, the following changes were introduced: cells were stimulated with 
TNFα for 10 min and then lysed in a modified denaturing buffer (lacking DOC). Precleared 
lysates were incubated with prewashed Strep-Tactin® XT resins.  
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Mass Spectrometric Analysis. Eluates obtained from Strep-Tactin® resins were resolved by 
SDS-PAGE, each gel lane was cut into 8-15 slices, alkylated with chloroacetamide and 
digested with trypsin (overnight, 37°C)56. Extracted peptides were desalted using C18 
StageTips57. A preliminary MS screen of linear polyUb-modified substrates was performed on 
an EASY-nLC™ II (Proxeon Biosystems) System coupled to an Orbitrap Elite (Thermo Fisher 
Scientific) Mass Spectrometer. Peptides were separated on a 15 cm and 75 µm ID PicoTip 
fused silica emitter (New Objective) in-house packed with ReproSil-Pur® C18-AQ 3 µm resin 
(Dr Maisch GmbH (Ltd.)). Peptides were eluted from the column using a segmented gradient 
of 5-50 % of solvent B (80 % ACN in 0.5 % acetic acid) at a constant flow rate of 200 nL/min 
over 87 or 127 min. The Mass Spectrometer was operated in positive ion mode and spectra 
were recorded in a mass range from m/z 300 to 2,000 with a resolution of 120,000. The 
twenty most intense ions were selected for collisional-induced dissociation (CID) 
fragmentation. For targeted MS inclusion lists containing up to 115 peptide masses of interest 
(ubiquitinated TRAF6 peptides and Ub peptides including modifications and GGM peptide) 
were exclusively selected for HCD fragmentation and MS/MS acquisition (R=15,000). 
Additional MS screening for the identification of novel linear polyUb targets was performed 
on an EASY-nLC™ 1200 System (Thermo Fisher Scientific) coupled to a Q Exactive™ HF 
(Thermo Fisher Scientific) Mass Spectrometer. Peptides were separated using a segmented 
gradient of 5-50 % of solvent B (80 % ACN in 0.5 % formic acid) at a constant flow rate of 
200 nL/min over 87 min on a 20 cm and 75 µm ID PicoTip fused silica emitter (New 
Objective) in-house packed with ReproSil-Pur® C18-AQ 1.9 µm resin (Dr Maisch GmbH 
(Ltd.)). The Q Exactive™ HF was operated in its positive mode. Full scans were acquired 
from m/z 300 to 1650 with a resolution of 120,000. The seven most intense ions were 
fragmented by higher-energy collisional dissociation (HCD) and MS/MS spectra recorded 
with a resolution of 60,000. Experiments were performed in triplicate. Obtained mass spectra 
were processed with the MaxQuant58 software suite (version 1.5.1.0) using the internal search 
engine Andromeda59 and searched against either the Uniprot Homo sapiens (release 2014_02; 
88,692 entries) database and a database containing INT-Ub and INT-Ub.7KR sequences or 
the Mus musculus (release 2014_02; 51402 entries) database. Carbamidomethylation (C) was 
set as fixed modification and acetylation (Protein N-term), oxidation (M), GlyGly (K, N-
term), deamidation (N, Q) were defined as variable modifications. In SILAC measurements, 
the amino acids K4/R6 and K8/R10 were defined as medium and heavy labels, respectively. 
Mass tolerance at the MS level was set to 4.5 ppm and to 0.5 Da at the MS/MS level (CID 
fragmentation), or 20 ppm (HCD fragmentation). The false discovery rate for peptides and 
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proteins was set to 1 %. An arbitrary cut-off of 2-fold change was used to determine 
significantly SILAC ratios. A functional enrichment analysis (Fisher´s exact test, p<0.01) of 
Gene Ontology and KEGG terms was performed in Perseus (version 1.5.0.15). 
siRNA Silencing. The following siRNAs (Eurofins Genomics) were used for knockdown: 
OTULIN1# GAC UGA AAU UUG AUG GGA A; OTULIN2# CAA AUG AGG CGG AGG 
AAU A; Hoip GAG GAC GGA GUU GUG AGG AUU UCC A and mock GGG AUA CCU 
AGA CGU UCU A. Knockdown studies were conducted as previously described20. 
Subcellular Fractionation. Cells were washed once with ice-cold PBS, resuspended in 100 
µl ice-cold buffer A (10 mM HEPES, pH 7.8; 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 5 
µg/ml aprotinin, 2 µM pepstatin, 10 µg/ml leupeptin, 1 mM PMSF, 5 mM NaF, 1 mM 
Na3VO4 and 0.5 % Triton X-100), incubated on ice for 10 min and then centrifuged (2000 
rpm, 5 min, 4°C). A supernatant was designated the cytoplasmic fraction. The pellet was then 
washed twice in ice-cold buffer A and resuspended in a 30 µl buffer C (50 mM HEPES, pH 
7.8; 420 mM KCl, 0.1 mM EDTA, 5 mM MgCl2, 10 % glycerol, 1 mM DTT 5 µg/ml 
aprotinin, 2 µM pepstatin, 10 µg/ml leupeptin, 1 mM PMSF, 5 mM NaF and 1 mM Na3VO4). 
After 30 min incubation on ice, the pellet was passed several times through a syringe and 
centrifuged (13000 rpm, 15 min, 4°C). The supernatant was designated the nuclear fraction. 
Luciferase Assays. Cells were plated on 6-well plates 24 h before transfection. pNFκB-Luc 
plasmid and β-Gal plasmid were transfected using either GeneJuice® (T-REx HeLa stable cell 
lines) or TurboFect (reconstituted TRAF6-/- MEFs). Twenty-four hours post transfection, cells 
were moved to medium lacking FBS for 16 h and then stimulated with either IL-1β (10 
ng/ml) or TNFα (20 ng/ml) for indicated times. Cell lysates were subjected to a luciferase 
assay according to the manufacturer's protocol (Roche). Internal control was measured by β-
Gal activity following the manufacturer's protocol (Roche). All experiments were done in 
biological triplicates, where each biological triplicate consisted of technical duplicates. 
Retroviral production. Untagged Ub and INT-Ub variants in pBabe–zeocine and HA-tagged 
mTRAF6 variants in pBabe–puromycin plasmids together with helper plasmid pHAI were 
transfected in HEK293T cells by using GeneJuice® (Merck Millipore). Thirty-six hours post 
transfection, media containing retroviruses were filtered, polybrene (4 mg/ml) was added and 
target cells (Ub variants into T-REx HEK293T/T-REx HeLa and TRAF6 mutants into 
TRAF6-/- MEFs) were infected. Forty-eight hours later cells were selected with medium 
containing either zeocine and blasticidin (Ub variants, 300 µg/ml and 10 µg/ml, respectively) 
 24 
or puromycin (TRAF6 mutants, 4 µg/ml) and kept in medium containing appropriate 
antibiotic(s). 
Statistical analysis. To determine statistical significance in Figures 2E, 2F, 6E and 
Supplementary Figure 2B, an unpaired, two-tailed Student’s t test was used. Three 
independent experimental replicates were performed in Figure 2E. Three independent 
experimental replicates consisting of three technical replicates were performed in Figures 2F 
and Supplementary Figure 2B. Four independent experimental replicates consisting of three 
technical replicates were performed in Figure 6E. For all of the figures, results are shown as 
means and error bars defined as s.e.m. **p<0.01, *p<0.05 were considered as significant, 
while p >0.05 was considered non-significant. T-values and degrees of freedom for t-tests 
were as follows: Figure 2E (t: between 0.0006743 and 2.054, df: 4), 2F (t: between 0.2587 and 
3.506, df: 4), 6E (t: between 2.892 and 5.612, df: 6) and Supplementary Figure 2B (t: 1.818, 
df: 4). For Figure 4B and 4C, where functional enrichment analysis of GO and KEGG terms 
was performed, Fisher´s exact test was used. p<0.01 was considered as significant. The 
analysis was performed by using Perseus software platform (version 1.5.0.15). 
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